Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Dr. Armstrong on the Utility of Liquid Biopsies in mCRPC

March 5th 2020

Andrew J. Armstrong, MD, discusses the utility of liquid biopsies in metastatic castration-resistant prostate cancer.

Real-World Analysis Confirms Enzalutamide Efficacy in mCRPC

March 4th 2020

Stephen J. Freedland, MD, discusses a real-world analysis of enzalutamide in patients with metastatic castration-resistant prostate cancer.

Antidepressant Shows Antitumor Potential in Prostate Cancer

March 4th 2020

The antidepressant phenelzine showed antitumor activity in patients with biochemical recurrent castrate-sensitive prostate cancer.

Dr. Dahut on an NCI-Led Study Using MRI Screening to Detect Prostate Cancer

March 4th 2020

William L. Dahut, MD, senior investigator and section chief, Genitourinary Malignancies Branch, head, Prostate Cancer Clinical Research Section, clinical director and scientific director for clinical research, Center for Cancer Research, National Cancer Institute (NCI), discusses an NCI-led study that is using screening to detect prostate cancer.

PROs Further Support Hypofractionated RT in Nonmetastatic Prostate Cancer

March 3rd 2020

The use of moderately hypofractionated radiation therapy demonstrated no statistically significant differences in functional outcomes compared with conventionally fractionated radiation therapy, further cementing hypofractionated radiation therapy as a standard approach for patients with nonmetastatic prostate cancer.

Dr. Powles on the Mission of the Uromigos Twitter Group

February 29th 2020

Thomas Powles, MD, MBBS, MRCP, discusses the mission and goals for the Uromigos Twitter group.

Dr. McKay on a Real-World Analysis of Radium-223 in mCRPC

February 27th 2020

Rana R. McKay, MD, discusses the results of a real-world analysis of radium-223 in patients with metastatic castration-resistant prostate cancer.

Dr. Agarwal on Developing Biomarkers of Response to Cabozantinib/Atezolizumab in mCRPC

February 27th 2020

Neeraj Agarwal, MD, discusses the importance of developing biomarkers of response to the combination of cabozantinib and atezolizumab in patients with metastatic castration-resistant prostate cancer.

Dr. Graff on Results of the KEYNOTE-199 Trial in mCRPC

February 27th 2020

Julie N. Graff, MD, discusses the results of the phase II KEYNOTE-199 trial in metastatic castration-resistant prostate cancer.

Dr. Oh on Remaining Challenges With Prostate Cancer Treatment

February 27th 2020

William K. Oh, MD, discusses remaining challenges with the advancing treatments in prostate cancer.

Dr. Grivas on Comparisons Between ATM and BRCA1/2 Mutations in mCRPC

February 27th 2020

Petros Grivas, MD, discusses comparisons between ATM and BRCA1/2 mutations in metastatic castration-resistant prostate cancer.

Researchers Building on Darolutamide Success in Prostate Cancer

February 26th 2020

Martin T. King, MD, PhD, discusses the INTREPId trial exploring darolutamide plus radiation therapy in patients with prostate cancer.

Neoadjuvant and Adjuvant ADT With Dose-Escalated PRT Show Similar Outcomes in Prostate Cancer

February 26th 2020

Neoadjuvant and concurrent androgen-deprivation therapy (ADT) with dose-escalated prostate radiotherapy (PRT) and concurrent and adjuvant ADT plus dose-escalated PRT were found to have no statistically significant differences in biochemical relapse-free survival in patients with localized prostate cancer, according to results of a phase III trial.

Dr. Tagawa on Preliminary Data With 225Ac-J591 in mCRPC

February 25th 2020

Scott T. Tagawa, MD, MS, discusses preliminary data with 225Ac-J591 in metastatic castration-resistant prostate cancer.

Dr. Armstrong on the Rationale of the PROPHECY Trial in mCRPC

February 21st 2020

Andrew J. Armstrong, MD, discusses the rationale of the PROPHECY trial in metastatic castration-resistant prostate cancer.

Dr. Tan on the Risk of Novel Coronavirus for Patients With Cancer

February 21st 2020

Christina Tan, MD, MPH, discusses the potential impact of the novel coronavirus on patients with cancer.

Dr. Fendler on Clinical Need for 68GA-PSMA-11 PET in Prostate Cancer

February 21st 2020

Wolfgang Fendler, MD, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at University of California, Los Angeles, discusses the clinical need for 68Ga-PSMA-11 PET in biochemically recurrent prostate cancer.

Dr. Graff on the KEYNOTE-199 Trial Design in Castration-Resistant Prostate Cancer

February 20th 2020

Julie N. Graff, MD, discusses the multi-cohort, phase II KEYNOTE-199 study examining patients with metastatic castration-resistant prostate cancer.

Increased Genetic Screening May Lead to Earlier Prostate Cancer Diagnoses

February 19th 2020

William L. Dahut, MD, discusses the natural history trial, the implications of the PROfound study, and the importance of screening for men at a high risk for developing prostate cancer.

Cabozantinib Plus Atezolizumab Active in mCRPC

February 19th 2020

The combination of cabozantinib and atezolizumab demonstrated clinically meaningful activity in patients with metastatic castration-resistant prostate cancer, including those with high-risk clinical features.